Olabisi Lab

Clinical Research

We are passionate about translating our research to the community affected by APOL1-mediated kidney disease.
African Americans represent 13% of U.S. population, more than 30% of people on dialysis but less than 5% of participants in therapeutic clinical trials.
Therefore, we go into Black community to engage, inform, provide free screening for APOL1-mediated kidney disease, and offer opportunity to eligible individuals to participate in APOL1-focused therapeutic trial (JUSTICE).